Stock Events

Stock Events

Cardiol Therapeutics 

$2.16
96
-$0.01-0.46% Thursday 19:59
-$0.01-0.46%Thursday 23:30After hours

Statistics

Day High
2.16
Day Low
2.15
52W High
2.28
52W Low
0.88
Volume
30,236
Avg. Volume
-
Mkt Cap
252.34M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

12NovExpected
Q3 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Q2 2026
Next
-0.19
-0.14
-0.1
-0.05
Expected EPS
-0.0760432270102
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
0Revenue
-24.31MNet Income

Analyst Ratings

9.50Average Price Target
The highest estimate is 10.00.
From 2 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow CRDL. It's not an investment recommendation.
NVIDIA
17
NVDA
Intel
13
INTC
AMD
12
AMD
Realty Income
11
O

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
AMGEN
AMGN
Mkt Cap233.78B
Amgen is a biotech company that develops treatments for cardiovascular diseases, directly competing with Cardiol Therapeutics' focus on heart disease therapies.
Pfizer
PFE
Mkt Cap159.36B
Pfizer develops a wide range of medications, including those for cardiovascular health, making it a competitor in the same therapeutic area as Cardiol Therapeutics.
Merck
MRK
Mkt Cap366B
Merck produces various cardiovascular drugs, competing in the same market as Cardiol Therapeutics.
Novartis
NVS
Mkt Cap292.35B
Novartis offers a portfolio of medicines for cardiovascular diseases, directly competing with Cardiol Therapeutics in the heart disease treatment space.
Bristol-Myers Squibb
BMY
Mkt Cap136B
Bristol Myers Squibb has a strong presence in the cardiovascular drug market, making it a direct competitor to Cardiol Therapeutics.
Abbvie
ABBV
Mkt Cap451.46B
AbbVie, through its acquisition of Allergan, has expanded its portfolio to include treatments for cardiovascular diseases, competing with Cardiol Therapeutics.
Gilead Sciences
GILD
Mkt Cap180.64B
Gilead Sciences, known for its work in antiviral drugs, also focuses on cardiovascular conditions, positioning it as a competitor to Cardiol Therapeutics.
Astrazeneca
AZN
Mkt Cap252.33B
AstraZeneca has a significant portfolio of cardiovascular drugs, making it a direct competitor to Cardiol Therapeutics in the market for heart disease treatments.
Johnson & Johnson
JNJ
Mkt Cap645.95B
Johnson & Johnson, through its pharmaceutical division Janssen, develops medications for cardiovascular diseases, competing with Cardiol Therapeutics.
Sanofi
SNY
Mkt Cap107.39B
Sanofi has a diversified healthcare portfolio that includes cardiovascular drugs, making it a competitor to Cardiol Therapeutics in the heart disease treatment market.

About

Cardiol Therapeutics Inc is a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease. Its primary small-molecule candidate, CardiolRx, targets inflammasome pathway activation, which is involved in the development of inflammation and fibrosis in conditions such as pericarditis, myocarditis, and heart failure. The CardiolRx program includes the completed Phase II MAVERIC-Pilot study and the ongoing Phase III MAVERIC trial for the treatment of pericarditis. The ARCHER program evaluated CardiolRx in acute myocarditis through a completed Phase II study. The company is also developing CRD-38, a novel subcutaneous drug formulation for treating inflammatory heart conditions, including heart failure.
Show more...
CEO
David G. Elsley
Employees
18
Country
Canada
ISIN
CA14161Y2006
WKN
000A2PA9E

Listings

STU
DE
CT9.STU
XNAS
US
CRDL
MU
DE
CT9.MU
TO
CA
CRDL.TO

0 Comments

Share your thoughts

FAQ

What is Cardiol Therapeutics stock price today?▼
The current price of CRDL is $2.16 USD — it has decreased by -0.46% in the past 24 hours. Watch Cardiol Therapeutics stock price performance more closely on the chart.
What is Cardiol Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Cardiol Therapeutics stocks are traded under the ticker CRDL.
Is Cardiol Therapeutics stock price growing?▼
CRDL stock has risen by +11.34% compared to the previous week, the month change is a +58.82% rise, over the last year Cardiol Therapeutics has showed a +94.59% increase.
What is Cardiol Therapeutics market cap?▼
Today Cardiol Therapeutics has the market capitalization of 252.34M
When is the next Cardiol Therapeutics earnings date?▼
Cardiol Therapeutics is going to release the next earnings report on November 12, 2026.
What were Cardiol Therapeutics earnings last quarter?▼
CRDL earnings for the last quarter are -0.04 USD per share, whereas the estimation was -0.07 USD resulting in a +48.28% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Cardiol Therapeutics revenue for the last year?▼
Cardiol Therapeutics revenue for the last year amounts to 0 USD.
What is Cardiol Therapeutics net income for the last year?▼
CRDL net income for the last year is -24.31M USD.
How many employees does Cardiol Therapeutics have?▼
As of September 04, 2026, the company has 18 employees.
In which sector is Cardiol Therapeutics located?▼
Cardiol Therapeutics operates in the Health & Wellness sector.
When did Cardiol Therapeutics complete a stock split?▼
Cardiol Therapeutics has not had any recent stock splits.
Where is Cardiol Therapeutics headquartered?▼
Cardiol Therapeutics is headquartered in Oakville, Canada.